がん診断薬市場：診断タイプ、適応症、成分、最終用途別-2025-2030年の世界予測

がん診断薬市場は、2023年に299億5,000万米ドルと評価され、2024年には333億1,000万米ドルに達すると予測され、CAGR 11.71％で成長し、2030年には650億6,000万米ドルに達すると予測されています。

がん診断薬市場には、患者のがん細胞、前がん状態、全体的な腫瘍負担を特定することを目的とした幅広い検査や処置が含まれます。これには、MRIやCTスキャンなどの画像診断、血液検査、生検、新しい遺伝子・分子診断技術などが含まれます。がん診断薬の必要性は、世界的にがんの有病率が高まっていることに起因しており、患者の転帰と生存率を大幅に改善できる早期発見と的を絞った治療計画の必要性を促しています。この市場の用途は様々ながん種に及び、エンドユーザーは病院、診断研究所、研究機関などです。主な成長促進要因としては、より精密な診断法につながる技術の進歩、資金提供や政策イニシアチブを通じた政府支援の増加、日常的ながん検診に対する認識と導入の拡大などが挙げられます。最近のビジネスチャンスは、低侵襲、迅速、高精度の診断オプションを提供するAI統合診断とリキッドバイオプシー技術の出現にあります。ゲノミクスと個人医療が統合されつつあることで、新たな市場ポテンシャルが開花し、特定のがんをターゲットとした診断薬の設計において企業がイノベーションを起こす余地が生まれています。しかし、先進的な診断ツールのコストが高い、規制当局の承認が厳しい、発展途上地域ではヘルスケア・インフラへのアクセスが限られている、といった課題が存在します。さらに、がんの種類は多様であり、病気の性質も複雑であるため、標準化された診断プロトコールには障壁があります。イノベーションを促進するためには、非侵襲的診断技術とAI能力に焦点を当てた研究への投資が不可欠です。さらに、テクノロジー企業とヘルスケアプロバイダーとのパートナーシップは、早期発見と治療効果のブレークスルーにつながる可能性があります。膨大な研究開発能力を保有する主要プレーヤーが支配する競合情勢を理解することは、このダイナミックな市場でのナビゲートと拡大を目指す企業にとって極めて重要であり、利害関係者にとって新技術と政策変更の継続的なモニタリングが不可欠となっています。

市場力学：急速に進化するがん診断薬市場の主要市場インサイトを公開

がん診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 若年層および老年層におけるがんの負担増
  • がん啓発のための政府の取り組みやキャンペーンの増加
  • がん診断に対する有利な償還の枠組み
• 市場抑制要因
  • がん診断機器の高コストとがん専門医の不足
• 市場機会
  • がんのスクリーニング、検出、診断のための革新的ツールの展開
  • がん診断におけるナノテクノロジーとナノ材料の統合
• 市場の課題
  • がん診断薬の不十分で誤った結果

ポーターの5つの力：がん診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、がん診断薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん診断薬市場における外部からの影響の把握

外部マクロ環境要因は、がん診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん診断薬市場における競合情勢の把握

がん診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん診断薬市場における成功への道筋を描く

がん診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 若年層と高齢者層におけるがんの負担増加
    • がん啓発のための政府の取り組みとキャンペーンの増加
    • がん診断に対する有利な償還枠組み
  • 抑制要因
    • がん診断機器の高コストと腫瘍医の不足
  • 機会
    • がんのスクリーニング、検出、診断のための革新的なツールの導入
    • がん診断におけるナノテクノロジーとナノマテリアルの統合
  • 課題
    • がん診断薬の不十分な結果と誤った結果
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん診断薬市場診断タイプ別

• 生検
• 血液化学検査
  • 全血球数（CBC）
  • 細胞遺伝学的分析
  • 免疫表現型検査
  • 液体生検
  • 喀痰細胞診
  • 腫瘍マーカー検査
  • 尿細胞診
• 画像検査
  • 骨スキャン
  • CTスキャン
  • 磁気共鳴画像（MRI）
  • 核スキャン
  • 陽電子放出断層撮影（PET）スキャン
  • 超音波
  • X線

第7章 がん診断薬市場適応症別

• 膀胱がん
• 血液がん
• 乳がん
• 大腸がん
• 腎臓がん
• 肝臓がん
• 肺がん
• 膵臓がん
• 前立腺がん
• 皮膚がん

第8章 がん診断薬市場：コンポーネント別

• 消耗品
• 機器
• ソフトウェア

第9章 がん診断薬市場：最終用途別

• 診断検査室
• 病院
• 研究センター

第10章 南北アメリカのがん診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のがん診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのがん診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 早期がんプラットフォームLabmate Onlineの開発を支える新たな資金
  • Owlstone Medical社、がんの早期発見を目的とした抗原標的 EVOCプローブの開発でBicycle Therapeutics社と提携
  • がん診断薬企業GenoME Diagnosticsが140万ポンドの資金調達を達成
  • IbexのGalen ProstateがIVDRに基づくCEマークを取得した初のスタンドアロンAI搭載がん診断薬ソリューションに
  • Dxcoverが1,000万ポンドを調達し、早期がん向けの画期的な液体生検プラットフォームを開発
  • マイクロソフト、ペイジと提携してがん診断薬と治療を推進
  • 富士フイルムインド、スーリヤ・ダイアグノスティクスLLPと提携し、ティルルでCTスキャンを開始
  • バイオケア・メディカルがエンパイア・ゲノミクスを買収
  • サーモフィッシャーがザ・バインディング・サイトと26億米ドルの契約を締結
  • Ibex MedicalがGalen 3.0がん診断薬プラットフォームを発表
  • ロシュは、タイムリーで的を絞った患者ケアを可能にするがん診断薬向けの新しいBenchMark ULTRA PLUSシステムを発売しました。
  • カルキノスヘルスケアが「がん診断薬と調査のための先進センター」を設立
  • BDはVitro S.A.からCytognosを買収し、がんの発見と診断から治療後のモニタリングへと事業を拡大しました。
  • ベクトン・ディキンソン、スペインの臨床フローサイトメトリー企業サイトグノスを買収
  • EarlySign、がんの早期発見のためのAIソリューションの商用化に向けた戦略的契約を発表
  • Cancer Diagnostics, Inc.がAnatech, Ltd.を買収
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Adaptive Biotechnologies Corporation
• Agilent Technologies, Inc.
• Becton, Dickinson & Company
• Bio-Techne Corporation
• bioMerieux SA
• Castle Biosciences Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Hologic Inc.
• Illumina, Inc.
• Johnson & Johnson Services, Inc.
• Konica Minolta, Inc.
• Koninklijke Philips N.V.
• Myriad Genetics
• Natera, Inc.
• Perkin Elmer, Inc.
• Personal Genome Diagnostics Inc.
• Qiagen N.V.
• Quest Diagnostics
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPLETE BLOOD COUNT (CBC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CYTOGENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPUTUM CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY URINE CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BONE SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CT-SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY NUCLEAR SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 65. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 68. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 70. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 98. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 99. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 100. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 102. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 105. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 106. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 108. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 133. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 142. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 146. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 147. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 148. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 151. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 152. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 153. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 154. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 156. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 157. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 158. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 159. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 160. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 162. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 170. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 171. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 172. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 173. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 174. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 175. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 176. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 177. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 178. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 179. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 181. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 182. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 183. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 184. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 185. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 187. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 188. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 189. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 190. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 191. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 193. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 194. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 195. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 196. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 197. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 199. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 200. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 201. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 202. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 203. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 204. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 205. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 206. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 207. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 208. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 209. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 211. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 212. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 213. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 214. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 215. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 217. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 218. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 219. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 220. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 221. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 223. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 224. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 225. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 226. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 227. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 228. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 229. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 230. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 231. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 232. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 233. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 234. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 235. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 236. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 237. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 238. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 239. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 240. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 241. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 242. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 243. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 244. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 245. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 246. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 247. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 248. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 250. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 251. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 252. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 253. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 254. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 256. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 257. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 258. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 259. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 260. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 261. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 262. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 263. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 264. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 265. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 266. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 267. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 268. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 269. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 270. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 271. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 272. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 273. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 274. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 275. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 276. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 277. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 278. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 279. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 280. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 281. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 282. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 283. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 284. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 285. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 286. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 287. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 288. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 289. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 290. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 291. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
• TABLE 292. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 293. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 294. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 295. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 296. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 297. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Diagnostics Market was valued at USD 29.95 billion in 2023, expected to reach USD 33.31 billion in 2024, and is projected to grow at a CAGR of 11.71%, to USD 65.06 billion by 2030.

The Cancer Diagnostics market encompasses a wide array of tests and procedures aimed at identifying cancerous cells, precancerous conditions, and overall tumor burden in patients. It includes imaging modalities like MRI and CT scans, blood tests, biopsies, and novel genetic and molecular diagnostic techniques. The necessity of cancer diagnostics stems from the growing prevalence of cancer globally, prompting the need for early detection and targeted treatment plans which can significantly improve patient outcomes and survival rates. This market's applications range across various cancer types, with end-users including hospitals, diagnostic laboratories, and research institutions. Key growth drivers include advancements in technology leading to more precise diagnostic methods, increased governmental support through funding and policy initiatives, and growing awareness and adoption of routine cancer screenings. Recent opportunities lie in the advent of AI-integrated diagnostics and liquid biopsy technologies, which offer minimally invasive, rapid, and highly accurate diagnostic options. The ongoing integration of genomics and personal medicine is also set to unlock new market potentials, giving businesses room to innovate in designing specific cancer-targeting diagnostics. However, challenges exist in the form of high costs of advanced diagnostic tools, stringent regulatory approvals, and limited access to healthcare infrastructure in developing regions. Additionally, the variability in cancer types and the complex nature of the disease create barriers to standardized diagnostic protocols. To foster innovation, investment in research focused on non-invasive diagnostic techniques and AI capabilities would be essential. Furthermore, partnerships between technology companies and healthcare providers can lead to breakthroughs in early detection and treatment effectiveness. Understanding the competitive landscape, dominated by key players who hold vast R&D capabilities, is crucial for businesses aiming to navigate and expand in this dynamic market, making continuous monitoring of emerging technologies and policy changes imperative for stakeholders.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Diagnostics Market

The Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing burden of cancer among younger and geriatric population
  • Rising government initiatives and campaigns for cancer awareness
  • Favorable reimbursement framework for cancer diagnosis
• Market Restraints
  • Associated high cost of cancer diagnostic equipment and lack of oncologists
• Market Opportunities
  • Deployement of innovative tools for cancer screening, detection, and diagnostics
  • Integration of nanotechnology and nanomaterials in cancer diagnosis
• Market Challenges
  • Inadequate and false results of cancer diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Diagnostics Market

A detailed market share analysis in the Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Diagnostics Market

A strategic analysis of the Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson & Company, Bio-Techne Corporation, bioMerieux SA, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Perkin Elmer, Inc., Personal Genome Diagnostics Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diagnostic Type, market is studied across Biopsy, Blood Chemistry Tests, and Imaging Tests. The Blood Chemistry Tests is further studied across Complete Blood Count (CBC), Cytogenetic Analysis, Immunophenotyping, Liquid Biopsy, Sputum Cytology, Tumor Marker Tests, and Urine Cytology. The Imaging Tests is further studied across Bone Scan, CT-Scan, Magnetic Resonance Imaging (MRI), Nuclear Scan, Positron Emission Tomography (PET) Scan, Ultrasound, and X-Rays.
• Based on Indication, market is studied across Bladder Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.
• Based on Components, market is studied across Consumables, Instruments, and Software.
• Based on End-Use, market is studied across Diagnostic Laboratories, Hospitals, and Research Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing burden of cancer among younger and geriatric population
    • 5.1.1.2. Rising government initiatives and campaigns for cancer awareness
    • 5.1.1.3. Favorable reimbursement framework for cancer diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
  • 5.1.3. Opportunities
    • 5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
    • 5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
  • 5.1.4. Challenges
    • 5.1.4.1. Inadequate and false results of cancer diagnostics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Diagnostics Market, by Diagnostic Type

• 6.1. Introduction
• 6.2. Biopsy
• 6.3. Blood Chemistry Tests
  • 6.3.1. Complete Blood Count (CBC)
  • 6.3.2. Cytogenetic Analysis
  • 6.3.3. Immunophenotyping
  • 6.3.4. Liquid Biopsy
  • 6.3.5. Sputum Cytology
  • 6.3.6. Tumor Marker Tests
  • 6.3.7. Urine Cytology
• 6.4. Imaging Tests
  • 6.4.1. Bone Scan
  • 6.4.2. CT-Scan
  • 6.4.3. Magnetic Resonance Imaging (MRI)
  • 6.4.4. Nuclear Scan
  • 6.4.5. Positron Emission Tomography (PET) Scan
  • 6.4.6. Ultrasound
  • 6.4.7. X-Rays

7. Cancer Diagnostics Market, by Indication

• 7.1. Introduction
• 7.2. Bladder Cancer
• 7.3. Blood Cancer
• 7.4. Breast Cancer
• 7.5. Colorectal Cancer
• 7.6. Kidney Cancer
• 7.7. Liver Cancer
• 7.8. Lung Cancer
• 7.9. Pancreatic Cancer
• 7.10. Prostate Cancer
• 7.11. Skin Cancer

8. Cancer Diagnostics Market, by Components

• 8.1. Introduction
• 8.2. Consumables
• 8.3. Instruments
• 8.4. Software

9. Cancer Diagnostics Market, by End-Use

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals
• 9.4. Research Centers

10. Americas Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
  • 13.3.2. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
  • 13.3.3. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
  • 13.3.4. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
  • 13.3.5. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
  • 13.3.6. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
  • 13.3.7. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
  • 13.3.8. Biocare Medical Acquires Empire Genomics
  • 13.3.9. Thermo Fisher ties up $2.6B deal for The Binding Site
  • 13.3.10. Ibex Medical launches Galen 3.0 cancer diagnostics platform
  • 13.3.11. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
  • 13.3.12. Karkinos Healthcare launches 'Advanced Centre For Cancer Diagnostics and Research'
  • 13.3.13. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
  • 13.3.14. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
  • 13.3.15. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
  • 13.3.16. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Adaptive Biotechnologies Corporation
• 3. Agilent Technologies, Inc.
• 4. Becton, Dickinson & Company
• 5. Bio-Techne Corporation
• 6. bioMerieux SA
• 7. Castle Biosciences Inc.
• 8. Danaher Corporation
• 9. Exact Sciences Corporation
• 10. F. Hoffmann-La Roche Ltd.
• 11. GE Healthcare
• 12. Hologic Inc.
• 13. Illumina, Inc.
• 14. Johnson & Johnson Services, Inc.
• 15. Konica Minolta, Inc.
• 16. Koninklijke Philips N.V.
• 17. Myriad Genetics
• 18. Natera, Inc.
• 19. Perkin Elmer, Inc.
• 20. Personal Genome Diagnostics Inc.
• 21. Qiagen N.V.
• 22. Quest Diagnostics
• 23. Siemens Healthineers AG
• 24. Sysmex Corporation
• 25. Thermo Fisher Scientific, Inc.